Butterfly Network Inc., a digital health company known for its handheld, whole-body ultrasound technology, has announced its involvement in an international research study named CAD LUS4TB. The study will evaluate the impact of AI-assisted point-of-care ultrasound (POCUS) on tuberculosis (TB) triage in under-resourced settings, specifically targeting Sub-Saharan Africa. The trial, which is set to begin in September, will involve 3,000 adult patients and will be conducted by non-radiologist healthcare workers using AI-led POCUS to identify potential TB indicators. The aim is to facilitate TB detection without requiring extensive ultrasound training or laboratory testing. The results of the trial are yet to be presented. This initiative also aspires to establish evidence-driven policies that integrate AI-aided lung ultrasound into national healthcare systems. Powered by Butterfly's Ultrasound-on-Chip™ technology, the company aims to enhance diagnostic imaging access and reduce morbidity and mortality from TB in low- and middle-income countries.